Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Endocrinology and Metabolism ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diabetes mellitus and visual impairment: national health and nutrition examination survey, 1999-2004.Arch Ophthalmol. 2008; 126: 1421-1427
- Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy.Diabetes Care. 2012; 35: 556-564
- Diabetic Retinopathy Data and Statistics. Www.Nei.Nih.Gov.(Available at:) (Accessed May 7, 2022)
- the wisconsin epidemiologic study of diabetic retinopathy. VII. Diabetic nonproliferative retinal lesions.Ophthalmology. 1987; 94: 1389-1400
- Differential glucose uptake in retina- and brain-derived endothelial cells.Microvasc Res. 2001; 62: 236-242
- Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy.Diabetes Obes Metab. 2008; 10: 53-63
- The pathogenesis of diabetic retinopathy: old concepts and new questions.Eye. 2002; 16: 242-260https://doi.org/10.1038/sj.eye.6700133
- Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.Ophthalmology. 1991; 98: 786-806
- Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.Vasc Health Risk Manag. 2008; 4: 575-596
- Fibrosis and diseases of the eye.J Clin Invest. 2007; 117: 576-586
- Prevalence of and risk factors for diabetic macular edema in the United States.JAMA Ophthalmol. 2014; 132: 1334-1340
- Diabetic macular edema pathophysiology: vasogenic versus inflammatory.J Diabetes Res. 2016; 2016: 2156273
- Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema.J Ophthalmol. 2019; 2019: 6274209
- Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 eraBMJ Open.Ophthalmology. 2021; 6: e000696
- Ophthalmic screening patterns among youths with diabetes enrolled in a large US managed care network.JAMA Ophthalmol. 2017; 135: 432-438
- Diabetic retinopathy - ocular complications of diabetes mellitus.World J Diabetes. 2015; 6: 489-499
- Diabetic retinopathy and the effect of pregnancy.Malays Fam Physician. 2010; 5: 2-5
- Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States.JAMA Ophthalmol. 2014; 132: 168-173
- Adherence to ophthalmology referral, treatment and follow-up after diabetic retinopathy screening in the primary care settingBMJ Open.Diabetes Res Care. 2020; 8: e001154
- Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography.Acta Ophthalmol Scand. 2001; 79: 266-270
- Optical coherence tomography angiography: a comprehensive review of current methods and clinical applications.Prog Retin Eye Res. 2017; 60: 66-100
- Ruby laser photocoagulation of early diabetic neovascular retinopathy: preliminary report of a long-term controlled study.Arch Ophthalmol. 1970; 83: 261-272
- The diabetic retinopathy study.Arch Ophthalmol. 1973; 90: 347-348
- Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy.Eye. 2009; 23: 2122-2123https://doi.org/10.1038/eye.2008.416
- Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review.Retina. 2007; 27: 816-824
- Anti-vascular endothelial growth factor therapy for diabetic macular edema.Ther Adv Endocrinol Metab. 2013; 4: 151-169
- Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial.Ophthalmology. 2016; 123: 1351-1359
- Diabetic retinopathy clinical research network. five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.JAMA Ophthalmol. 2018; 136 ([Erratum in: JAMA Ophthalmol. 2019 Apr 1;137(4):467. PMID: 30043039; PMCID: PMC6233839]): 1138-1148
- Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.Retina. 2006; 26: 275-278
- Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.N Engl J Med. 2015; 372: 1193-1203
- Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.Ophthalmology. 2012; 119: 789-801
- Intravitreal aflibercept for diabetic macular edema.Ophthalmology. 2014; 121: 2247-2254
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.Angiogenesis. 2012; 15: 171-185
- Comparing the efficacy of bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME): the brdme study, a randomized trial.Oph Retina. 2020; 4: 777-788
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.JAMA. 2015; 314 ([Erratum in: JAMA. 2016 Mar 1;315(9):944. Erratum in: JAMA. 2019 Mar 12;321(10):1008. PMID: 26565927; PMCID: PMC5567801]): 2137-2146
- FDA approves Genentech's Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States.(Available at:)https://www.gene.com/media/press-releases/14661/2017-04-17/fda-approves-genentechs-lucentis-ranibiz(Accessed May 30, 2018)Date: 2015
- Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study.Ophthalmology. 2019; 126: 1171-1180
- Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.Ophthalmology. 2015; 122: 367-374
- Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial.JAMA Ophthalmol. 2021; 139: 946-955
- Effect of intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial.JAMA Ophthalmol. 2021; 139: 701-712
- Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.Am J Ophthalmol. 2001; 131: 468-471
- Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.Am J Ophthalmol. 2001; 132: 425-427
- Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.Ophthalmology. 2010; 117: 1064-1077.e35
Allergan receives FDA approval for Ozurdex biodegradable, injectable steroid implant with extended drug release for retinal disease. Drugs.com. 2009. Available at:https://www.drugs.com/newdrugs/allergan-receives-fda-approval-ozurdex-biodegradable-injectable-steroid-implant-extended-release-1473.html. Accessed May 7, 2022.
- Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.Ophthalmology. 2014; 121: 1904-1914
- Surgery for diabetic eye complications.Curr Diab Rep. 2016; 16: 99
- Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol t extension study).Ophthalmology. 2020; 127: 1201-1210
- Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.Ophthalmology. 2015; 122: 375-381
- Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.Br J Ophthalmol. 2021; 105: 216-221
- Health Care Utilization and Costs of Diabetes.in: Cowie C.C. Casagrande S.S. Menke A. Diabetes in America. 3rd edition. National Institute of Diabetes and Digestive and Kidney Diseases (US), Bethesda (MD2018 (CHAPTER 40. Available at:) (Accessed 7 May 2022)
- Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema.Ophthalmology. 2019; https://doi.org/10.1016/j.ophtha.2019.03.023
- FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Roche.(Available at:) (Accessed December 29, 2021)
- YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.Lancet. 2022; 399: 741-755
- Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration.Ophthalmologica. 2021; 244: 93-101
- KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema.Am J Ophthalmol. 2022; 13https://doi.org/10.1016/j.ajo.2022.01.004
- FDA approves Genentech’s Susvimo, a first-of-its-kind therapeutic approach for wet age-related macular degeneration (AMD) [press release].Genentech, San Francisco,CA2021 (Available at:) (Accessed January 2, 2022)
- Genentech initiates phase 3 trial for port delivery system with ranibizumab in diabetic retinopathy. Eyewire+.(Available at:) (Accessed May 7,2022)
- Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.Ophthalmology. 2012; 119: 2125-2132
- RegenxBio presents additional positive interim data from trials of RGX-314 in wet AMD and diabetic retinopathy using suprachoroidal delivery at AAO 2021 [news release]. RegenxBio, Rockville, MD2021 (regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-presents-additional-positive-interim-data-trials-rgx)
- Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs.JAMA. 2016; 316: 2402-2410
- Retinal Physician - An Update on Artificial Intelligence and Deep Learning in Retina. Retinal Physician.(Available at:) (Accessed May 8, 2022)
Article info
Publication history
Published online: November 17, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
